AHA Scientific Sessions 2023
Evinacumab reduces atherogenic lipids in children and adolescents with HoFH
Comparable reductions in atherogenic lipids have been reported in studies of children with HoFH aged 5-11 years treated with evinacumab (NCT04233918) and in those aged 12-17 years (NCT03409744). In 14 patients aged 5-11 years with HoFH who received evinacumab 15 mg/kg i.v. every four weeks…
read more »
Heart-1 trial: Interim data show PCSK9 gene editing lowers LDL-C
VERVE-101, a CRISPR-based gene editing therapy, significantly reduces LDL-C in patients with HeFH and established atherosclerotic cardiovascular disease (ASCVD), according to interim results from the ongoing Phase 1b, heart-1 study (NCT05398029). The heart-1 trial is designed to evaluate the safety and tolerability of VERVE-101, with…
read more »
EBBINGHAUS study reassures about cognitive safety with long-term PCSK9 inhibition
No apparent long-term decline in cognitive function linked to evolocumab has been found in over seven years of follow up in EBBINGHAUS, a prespecified substudy within the FOURIER trial. Of 1204 patients from EBBINGHAUS, 306 entered the open label extension (OLE) and were treated with…
read more »
